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AbstrAct
A considerable proportion of the human genome consists of transposable 
elements, including the long terminal repeats (LTRs) of endogenous retroviruses. 
During evolution, such LTRs were occasionally inserted upstream of protein-coding 
genes, contributing to their regulation. We previously identified the LTR12 from 
endogenous retrovirus 9 (ERV9) as a regulator of proapoptotic genes such as TP63 or 
TNFRSF10B. The promoter activity of LTR12 is largely confined to the testes, silenced 
in testicular carcinoma, but reactivated in testicular cancer cells by broad-range 
histone deacetylase (HDAC) inhibitors. Here we show that inhibition of HDAC1-3 is 
sufficient for LTR12 activation. Importantly, HDAC inhibitors induce LTR12 activity not 
only in testicular cancer cells, but also in cells derived from many additional tumor 
species. Finally, we characterize the transcription factor NF-Y as a mediator of LTR12 
promoter activity and HDAC inhibitor-induced apoptosis, in the context of widespread 
genomic binding of NF-Y to specific LTR12 sequences. Thus, HDAC inhibitor-driven 
LTR12 activation represents a generally applicable means to induce proapoptotic 
genes in human cancer cells.
IntroductIon
The majority (45 to 69%) of the human genome 
consists of transposable elements [1, 2]. One class of such 
elements is represented by long terminal repeat (LTR)-
containing retrotransposons, also known as endogenous 
retroviruses (ERVs), which account for roughly 8% of 
the human genome [3, 4]. ERVs are considered remnants 
of ancient retroviral infections that occurred millions of 
years ago [5, 6]. During a retroviral life cycle, a provirus 
is inserted into the host’s genome [7, 8].When a provirus 
is inserted in cells of the germline, it can be passed on 
in a stable manner according to the Mendelian laws, 
thus becoming endogenized [7, 9]. As a consequence, 
full-length ERVs contain the viral genes gag, pol and 
sometimesenv, flanked by two LTRs [6, 7, 10]. However, 
the vast majority of ERV-derived sequences in the human 
genome are solitary LTRs [7]. They most probably arose 
through homologous recombination between two LTRs, 
resulting in the loss of the retroviral genes between them 
[11, 12]. LTRs contain important gene regulatorysequence 
elements, such as promoters and enhancers [6, 13]. When 
inserted in close proximity to a host gene, LTRs can 
influence its expression pattern [14]. However, little is 
known about the factors that regulate the promoter activity 
of LTRs, and about the functional consequences of such 
LTR activities in human cells.
Since the mobility of transposable elements is 
potentially harmful to the host through disruption or 
de-regulation of genes, various mechanisms evolved in 
order to restrict their general activity. Among these are 
DNA methylation, small inhibitory RNAs and histone 
modifications [15-18]. Such modifications can diminish 
the promoter activity of retroviral LTRs, interfering with 
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the transcription of downstream virus genes and thus 
preventing the spread of ERVs through the genome. 
However, concepts for the specific and dynamic regulation 
of single LTRs in human cells are lacking. 
An LTR of the HERV-9 (ERV9) family was 
previously characterized in our laboratory as to its 
promoter activity, in particular at two genomic locations 
[19, 20]. This LTR is termed LTR12 according to the 
database of repetitive elements Repbase [21]. First, we 
found that LTR12 confers the tissue-specific expression 
of GTAp63, a testicular isoform of the p53 tumor 
suppressor homologue p63 derived from the gene TP63, 
in male germ cells [20]. Furthermore, an LTR12 inserted 
upstream of TNFRSF10B drives its expression in testis 
[19]. TNFRSF10B, also known as Killer/DR5, encodes 
a death receptor that transmits the proapoptotic signal of 
Trail [22, 23].
Interestingly, transcription of LTR12-driven 
TNFRSF10B and TP63was enhanced by more than 1000-
fold in testicular cancer cells upon treatment with the 
HDAC inhibitors (HDACi) Trichostatin A (TSA) as well 
as the structurally similar suberoylanilidehydroxamic 
acid (SAHA) [19, 20]. Functionally, this enhanced 
LTR12 promoter activity resulted in elevated levels of the 
TNFRSF10B gene product, death receptor 5 (DR5), and 
testicular cancer cell death. 
The trimeric nuclear factor Y (NF-Y) associates 
with LTR12. NF-Y is composed of the three subunits 
named NF-YA, NF-YB and NF-YC.While NF-YA 
confers sequence-specificity for the DNA motif CCAAT, 
NF-YB and NF-YC have histone-like structural features 
to bind DNA with broader specificity [24, 25]. Binding 
of NF-Y to an LTR12 upstream of the beta-globin locus 
control region can influence its enhancer activity through 
the recruitment of additional transcription factors [26]. 
Moreover, a genome-wide search for NF-Y binding 
sites in the human genome revealed clustering at HERV 
LTRs, in particular at LTR12s and MLT1 LTRs [27]. 
The functional relevance of this association, however, 
remains to be determined. In general, NF-Y is implied 
in gene activation as well as gene repression, and it can 
associate with histone acetyl transferases (HATs) but 
also deacetylases [28-32]. While acetylation of histones 
by HATs is believed to mostly relax the chromatin and 
render it more accessible to the transcription machinery, 
deacetylation opposes these effects [33, 34]. Histone 
deacetylases, which remove acetyl groups from histones, 
also have non-histone substrates such as transcription 
factors and chaperone proteins [35, 36]. The molecular 
responses to alterations in HDAC activity range from 
apoptosis, migration and differentiation to angiogenesis 
[37-39]. HDACs are commonly divided into four classes.
HDACs of class I (HDAC1, 2, 3 and 8), IIa (HDAC4, 5, 7 
and 9), IIb (HDAC10 and 6) and IV (HDAC11) each carry 
a zinc ion(Zn2+) at their active sites [40-42]. Hence, these 
HDACs are characterized as zinc-dependent HDACs and 
can be inhibited by agents that compete with the substrate 
for interaction with the zinc ion [42]. In some cancers, 
particular HDACs are overexpressed [43], and inhibition 
of HDAC activity can represent an efficient anticancer 
treatment. Aside from the HDAC inhibitors SAHA and 
romidepsin, which are approved for the treatment of 
cutaneous T-cell lymphoma [42, 44, 45], various other 
HDAC inhibitors are currently undergoing clinical trials 
for the treatment of different tumors, including lymphomas 
and solid tumors [42, 44]. Some of these HDAC inhibitors 
are specific for certain classes or even individual HDACs 
[37, 44].
Here, we sought to determine how HDAC inhibitors 
increase LTR12 promoter activity and whether these 
mechanisms are also accessible in cancer cells that were 
not derived from testicular carcinoma. We observed 
strong enhancement of LTR12-driven gene transcription 
upon treatment with HDAC inhibitors that selectively 
target HDAC 1/2/3. The transcription factor NF-Y was 
found to be involved in LTR12 regulation. Of particular 
note, LTR12 promoter activity was not only observed 
in testicular cancer cells but was strongly increased by 
HDAC inhibitors in a broad variety of human cancer cells.
results
Inhibitors of HdAcs 1-3 induce ltr12 promoter 
activity
Based on our previous observations that LTR12-
driven gene transcription is strongly induced bythe 
hydroxamate HDAC inhibitors TSA and SAHA [19, 
20], we now tested a panel of HDAC inhibitors from 
different chemical classes as to their influence on LTR12 
promoter activity. Testicular cancer-derived GH cells 
were treated with 0.5/2/8 µM of HDAC inhibitors for 18 
h. Subsequently, the relative gene expression levels of 
LTR12-driven TP63 (GTAp63) and TNFRSF10B were 
assessed by qRT-PCR. Aside from TSA, LTR12 promoter 
activity was significantly increased upon treatment 
with Entinostat, Mocetinostat and to a lesser extent 
withTubastatin A (Figure 1). While TSA and SAHA bind 
all eleven zinc-dependent HDACs [46], Mocetinostat and 
Entinostat are selective inhibitors for HDACs 1, 2 and 3 
[37]. Thus, inhibition of HDACs 1-3 appears to make the 
largest contribution to the activation of LTR12. Moreover, 
we conclude that benzamide HDAC inhibitors, as well 
ashydroxamic acid HDAC inhibitorseach activate LTR12. 
This largely precludes off target effects but confirms the 
notion that HDAC inhibition is indeed the key mechanism 
of LTR12 activation.
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Figure 1: LTR12 induction by inhibitors of HDACs 1-3 in GH cells treated with HDAC inhibitors from different 
chemical classes. Cells were treated with increasing concentrations of each inhibitor (0.5 µM, 2 µM, 8 µM) for 18 h. Subsequently, 
relative gene expression was assessed by qRT-PCR. The levels of mRNA corresponding to the TP63 isoform GTAp63 and to the LTR 
transcript 2 of TNFRSF10B are depicted. A significant increase in transcription of the LTR12-driven isoforms of TP63 and TNFRSF10B was 
observed upon treatment with Trichostatin A, Entinostat, Mocetinostat and Tubastatin A. For all tested HDAC inhibitors, their specificities 
for each known HDAC are indicated, according to the average IC50 values as indicated at PubChem (https://pubchem.ncbi.nlm.nih.gov/). 
mRNA levels were normalized to RPLP0 and are shown as a fold change of DMSO-treated control cells. Error bars represent the standard 
deviation, SD (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001. IC50 values for the HDAC inhibitors are represented as follows: +++ < 10 
nM; ++ 10 nM-1 µM; + 1-10 µM; - > 10 µM. n. d., not determined.
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HdAc inhibitors induce ltr12 promoter activity 
in cells from various tumor species
LTR12-driven transcription is present in normal 
testis, but silenced in testicular cancer cells [20]. However, 
treatment with HDAC inhibitors results in strong de-
repression of the LTR12 promoter activity [19, 20]. We 
now asked whether this mechanism is also accessible in 
tumor cells derived from tissues other than testis. A panel 
of human cancer cell lines was treated with TSA (0.5/1/2 
µM) and SAHA (1/5 µM) over a period of 18 h. This 
included GH (testis cancer), H1299 (lung carcinoma), 
HeLa (cervical carcinoma), Ovcar-3 (ovarian carcinoma), 
U2OS (osteosarcoma), K562 (leukemia) and HuT-78 
(cutaneous T-cell lymphoma) cells.Of note, cutaneous 
Figure 2: ltr12 induction by HdAc inhibitors in cell lines from various tumor species. Human cell lines derived from 
varioustumor origins were treated with the HDAC inhibitors Trichostatin A (TSA) or suberoylanilidehydroxamic acid (SAHA) at increasing 
concentrations (0.5 µM,1 µM, 2 µM for TSA and 1 µM, 5 µM for SAHA) for 18 h, followed by qRT-PCR analysis. Cells treated with 
DMSO alone were used as controls. mRNA levels were normalized to RPLP0. The mRNA levels corresponding to LTR-driven GTAp63 
and TNFRSF10BLTR transcript 2 [19] are depicted. Strong increases in transcription for both LTR-driven transcripts were observed in all 
tested cell lines. For a comparison with overall levels of TP63 and TNFRSF10B mRNA, see Supplemental Figure S1. The cell lines were 
GH (testicular cancer), H1299 (lung carcinoma), K562 (leukemia), U2OS (osteosarcoma), HeLa (cervical carcinoma), Ovcar-3 (ovarian 
carcinoma) and HuT-78 (cutaneous T-cell lymphoma). Error bars represent the SD (n = 3). *, p < 0.05; **, p < 0.01, ***; p < 0.001.
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T-cell lymphoma is the tumor entity where SAHA (alias 
Vorinostat) represents the FDA-approved treatment option 
[47]. Assessment of LTR12-driven gene transcription 
revealed a strong (up to several hundred-fold) increase 
in the transcription of both GTAp63 (Figure 2, upper 
panel) and LTR12-driven TNFRSF10B (Figure 2, lower 
panel) in all cell lines. In parallel, the total levels of TAp63 
and TNFRSF10B were quantified, including transcripts 
starting from the previously described sites within non-
LTR, “host” gene promoters. Here, the increase in 
transcription was still observed, but less strongly (Suppl. 
Figure S1). We propose that the LTR12 promoters, but 
not the additional promoters of the genes under study, are 
activated by HDAC inhibitors, resulting in a moderate 
Figure 3: HdAc inhibitors inducing exclusively ltr12 but not other ltrs from endogenous retroviruses. U2OS cells 
were treated with the HDAC inhibitors Trichostatin A (TSA) or suberoylanilidehydroxamic acid (SAHA) or the DMSO solvent alone, using 
increasing concentrations (0.5 µM, 1 µM, 2 µM for TSA and 1 µM, 5 µM for SAHA) for 18 h, followed by qRT-PCR with normalization 
to RPLP0. The mRNA levels corresponding to LTR12-driven isoforms of different cellular genes [A] and to cellular genes driven by LTRs 
from other ERV families and envelope genes of the endogenous retroviruses HERV-K and HERV-W [B] are depicted. Strongly enhanced 
transcription was observed for all six genes driven by an LTR12 (HERV-9 LTR). In contrast, little or no enhancement by TSA was found 
for the transcription of genes driven by LTRs other than LTR12, as we found previously for testicular GH cells [19]. Error bars represent 
the SD (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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increase when analyzing the mixed population of mRNAs. 
In conclusion, HDAC inhibitors strongly activate LTR12-
driven transcription not only in testicular cancer cells, 
but in a variety of cell lines derived from multiple tumor 
species.
HdAc inhibitors induce the promoter activities of 
LTR12 but not of LTRs from different endogenous 
retroviruses
Next, we addressed the question whether additional 
LTRs from various endogenous retroviruses might be 
subject to activation by HDAC inhibitors. We treated 
U2OS cells with TSA (0.5/1/2 µM) and SAHA (1/5 µM) 
and assessed the transcription of six LTR12-driven host 
genes but also HERV-E-driven APOC1, two HERV-
H-driven host genes, MaLR-driven IL2RB, and viral 
envelope genes of HERV-K and HERV-W. As a result, 
we observed a specific induction of LTR12-regulated 
transcription (Figure 3A) [19] but not that of other LTRs 
in response to HDAC inhibition (Figure 3B), as we had 
seen previously with testicular GH cells [19]. Hence, the 
strong enhancement of LTR promoter activity by HDAC 
inhibitors is specific for ERV9 LTRs but does not pertain 
to different human ERV promoter elements. On the other 
hand, LTR12s do not depend on their specific integration 
site to function as HDAC inhibitor-responsive promoters.
Various ltr12s in the human genome show 
consensus nF-Y binding sites and associate with 
nF-Y
Based on the uniform activation of the ERV9-LTR12 
but no other LTRs by HDAC inhibitors, we considered 
the possibility that a common LTR12-binding transcription 
factor might be involved in its promoter activation. One 
transcription factor that was previously implied in LTR12 
promoter regulation is nuclear factor Y (NF-Y) [26, 
48]. In-silico prediction of putative NF-Y binding sites 
within twenty-two different HDAC inhibitor-responsive 
LTR12s (Suppl. Figure S2) revealed the presence of 
seven sites on average within each LTR12. Alignment of 
the analyzed LTR12 sequences showed that the position 
of some NF-Y binding sites was conserved throughout 
most sequences (Figure 4A; Suppl. Figure S2). NF-Y 
binding site “-1”, for example, was predicted in 91% of 
all analyzed sequences and in a constant distance of 37 
nucleotides from the first TATA box (Suppl. Table S2). In 
line with our prediction, a recent genome-wide Chromatin 
Immunoprecipitation (ChIP) study of NF-Y binding sites 
in three human cell lines revealed that a bulk of these 
sites overlapped with endogenous retroviral LTRs [27]. 
To identify the occupancy of LTR12s with NF-Y, we 
retrieved the NF-Y binding sites identified by Fleming 
et al. [27] and searched them for regions corresponding 
to LTR12 sequences. In HeLa-S3 cells, about 19% of all 
LTR12 locations in the human genome were found to be 
bound by an NF-Y subunit. Even more impressively, 70% 
of LTR12s bound NF-Y in K562 cells (Figure 4B). For 
GM12878 cells, 54% of all LTR12 sites were occupied by 
NF-Y. This included the LTR12s upstream of TP63 and 
TNFRSF10B, as depicted in Figure 4C. We also searched 
for NF-Y-associated sites with LTRs from other HERV 
families, e. g. LTR2 of the HERV-E family, and observed 
a much lower occupancy with NF-Y (between 0% and 
0.5%; Suppl. Figure S3). Taken together, we conclude that 
NF-Y is not only predicted to bind LTR12s, but actually 
bound to LTR12 promoter elements in different human 
cell species with high abundance and specificity.
NF-Y binds LTR12, and the interaction is fortified 
by HdAc inhibition
To determine whether NF-Y was also present on 
LTR12 in a testicular context, and whether its binding 
pattern was subject to regulation by HDAC inhibitors, 
we assessed NF-Y chromatin binding in testicular cancer 
cells. Coordinates of NF-Y peaks within LTR12 sequences 
were first retrieved from the genome-wide analyses in 
HeLa, GM12878 and K562 cells (Suppl. Table S3). Of 
note, many but not all LTR12 sites were occupied by 
NF-Y; the selectivity of binding might be determined by 
other transcription factors and/or the chromatin structure. 
According to the sites of maximum NF-Y association, 
primers for amplification of the LTR12s adjacent to 
DHRS2, PGPEP1L, TNFRSF10B and TP63 were 
designed, which gave rise to the expected PCR products 
when tested on genomic DNA. After treatment with TSA 
or its solvent DMSO, testicular cancer cells were subjected 
to chromatin harvesting and immunoprecipitation with an 
antibody recognizing NF-Y subunit beta (NF-YB). The 
inactive promoter region of the myoglobin gene MB was 
analyzed as a negative control. CCNB1/Cyclin B1, which 
is strongly bound by NF-Y [49], was detected as a positive 
control. In untreated cells, NF-YB was bound to CCNB1, 
as well as to all four analyzed LTR12 promoter elements 
(Figure 5). Upon treatment with TSA, the interaction of 
NF-Y with all four LTR12s increased between two- and 
four-fold. This indicates that NF-Y is not only present at 
the endogenous retroviral promoter elements in testicular 
cancer cells, but that its binding increases in response to 
treatment with TSA.
nF-Y is a determinant of ltr12 promoter activity 
and tsA-mediated apoptosis
Finally, we determined how NF-Y affects the 
promoter activity of LTR12 in the presence or absence of 
HDAC inhibitors. To this end, we removed the subunits 
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Figure 4: nF-Y binding sites within ltr12. A. Predicted NF-Y binding sites within LTR12. NF-Y binding sites (grey boxes) within 
HDAC inhibitor-responsive LTR12 promoter elements (red), as predicted by in-silico analysisusing the ALGGEN PROMO tool (http://
alggen.lsi.upc.es/) [61, 62]), are indicated. Moreover, TATA boxes (AATAAA) are shown. The numbers represent the average distances 
between binding sites in nucleotides upon alignment of the LTR12s using CLUSTALW, cf. Supplemental Table S1. Twenty-two LTR12s 
were included in the analysis. The alignment is shown in Supplemental Figure S2. Boxes framed in black indicate binding sites that are 
present in more than 65% of all analyzed LTR12s, whereas grey frames indicate less frequent binding sites. b. Confirmed NF-Y binding 
sites are enriched within LTR12s. ChIP-seq data that indicate binding of the NF-Y subunits alpha (NF-YA) and beta (NF-YB) [27] were 
retrieved from GEO and analyzed for binding sites with LTR12 locations. NF-Y binding was analyzed in K562 cells, HeLa-S3 cells, and 
GM12878 cells, as detailed in Supplemental Table S3. Note that not all locations are detectably bound by both subunits. The association 
of NF-Y to LTR12s differs between the three cell lines. Between 19% and 70% of the analyzed LTR12s were bound by NF-Y. In contrast, 
LTRs from different ERVs have far lower occupation with NF-Y, as depicted in Supplemental Figure S3. c. ChIP-Seq tracks of the LTR12s 
upstream of TP63 and TNFRSF10B. ChIP-seq data for binding of the NF-Y subunits alpha (NF-YA, green) and beta (NF-YB, blue), 
according to [27], were retrieved from GEO for HeLa, K562 and GM12878 cells. Bar charts of binding intensities at the LTR12 promoters 
upstream of TP63 (upper panel) and TNFRSF10B (lower panel) are presented. The location of the TATA1 box (see Figure 4A) within each 
LTR12 is indicated by a black bar.
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alpha (NF-YA; Figure 6A and Suppl. Figure S4A) and beta 
(NF-YB; Suppl. Figure S4B, S4C) of NF-Y by shRNA-
mediated knockdown, followed by TSA-treatment. 
Knockdown of each subunit was highly efficient as 
demonstrated by Western blot analysis and qRT-PCR 
(Suppl. Figure S4A-S4C).
The removal of NFY-A resulted in a decreased 
expression of the LTR12-driven genes CGREF1, DHRS2 
and SEMA4D, both in TSA- and in DMSO-treated cells 
(Figure 6A). Depletion of NF-YB also reduced the levels 
of LTR12-driven mRNAs, but with lower significance 
(Suppl. Figure S4D). LTR12-driven TNFRSF10B 
expression, in contrast, was augmented by removal of NF-
YA, but not NF-YB. This is in line with a proapoptotic 
effect of NF-YA inactivation [50], possibly secondary to 
the activation of p53 [22, 49]. TNFRSF10B is a known 
p53-inducible gene [22, 23] and in this aspect differs from 
other LTR12-driven genes. NF-YA depletion reduced the 
cleavage of poly-ADP-Ribose Polymerase (PARP) and 
caspase 3 upon treatment with TSA (Figure 6B). Overall, 
we conclude that the activity of LTR12 is generally 
supported by NF-Y. Furthermore, TSA-mediated apoptosis 
is supported by NF-Y.
dIscussIon
LTR12, a driver of proapoptotic genes, can be 
induced by pharmacological HDAC inhibition. Our 
results show that the specific inhibition of HDACs 1, 2, 
and 3 is sufficient for LTR12 induction, making these 
HDACs primary candidates for LTR12 regulation. 
Strikingly, the enormous upregulation of LTR12-driven 
genes by HDAC inhibitors is not confined to cells from 
germline tumors. Instead, a large variety of cells derived 
from different tumor species showed LTR12 inducibility 
by the same agents. On the other hand, the induction by 
HDAC inhibitors is confined to the LTR12, derived from 
ERV9, but is largely absent from the LTRs from different 
endogenous retroviruses. Finally, NF-Y was not only 
found to associate with LTR12 but also to enhance its 
promoter activity.
the role of HdAcs 1-3 in ltr12 activation
Among the tested inhibitors, TSA, SAHA, 
Mocetinostat and Entinostatinduced strong LTR12 
promoter activation.What these compounds have in 
common is their ability to inhibit the HDACs1-3. Thus, 
these three HDACs appear most responsible for the 
regulation of LTR12. HDACs 1-3 are also structurally 
related, and all three belong to class I of HDACs, based 
on their structural similarities and their homology to yeast 
RPD3 [38]. Members of this class of HDACs are not only 
Figure 5: Increased binding of nF-Yb to ltr12s after treatment with tsA. GH cells were treated with 0.5 µM TSA or the 
DMSO solvent as indicated. Subsequently, Chromatin immunoprecipitation (ChIP) was performed with antibodies to NF-YB or a pre-
immune control antibody. The DNA corresponding to the indicated promoters was quantified by real-time PCR and displayed in relation to 
the amount of input DNA. Bars indicate the standard error from three independent experiments.
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targets of TSA and SAHA, but more specific additional 
inhibitors for these HDACs are in clinical development 
for cancer treatment [37]. It is conceivable that such 
novel HDAC inhibitors operate, at least in part, through 
the activation of LTR12. Of note, cancer is not the only 
indication for which HDAC inhibitor-based therapies 
Figure 6: Positive regulation of ltr12 activity by nF-Y. A. HeLa cells were depleted of NF-YA by shRNA as described [49, 64], 
and depletion was confirmed as shown in cf. Supplemental Figure S4A. The cells were then treated with 2 µM TSA for 18 h, and relative 
gene expression was assessed by qRT-PCR with normalization to RSP20. The transcription levels of Cyclin B2/CCNB2, PHGDH (positive 
controls responding to NF-Y depletion) as well as four LTR12-driven genes (CGREF1, DHRS2, SEMA4D, TNFRSF10B) are depicted. 
A significant decrease in transcription of the LTR-driven isoforms was observed upon removal of NF-YA for CGREF1 and DHRS2 as 
well as for PHGDH.SD (n = 2). *, p < 0.05; **, p < 0.01; ***, p < 0.001. b. Upon treatment as in A, caspase cleavage was determined by 
immunoblot analysis. Vinculin staining served as a loading control. Poly-ADP Ribose Polymerase (PARP) and Caspase 3 were detected at 
two different molecular weights each. The upper bands represent the full-length proteins, whereas the lower bands correspond to fragments 
generated by caspase-mediated cleavage, reflecting apoptosis.
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are tested. Rather, HDAC inhibitors targeting class I 
HDACs are used in trials to treat neurodegenerative 
diseases as well [51]. It remains to be tested whether 
LTR12 expression can also be induced in degenerating 
neurons upon HDAC inhibitor treatment, and if so, 
whether this represents an obstacle or rather contributes 
to the beneficial effects of the drugs. In any case, LTR12-
driven genes are certainly not the only ones that respond 
to HDAC inhibitors, although LTR12 mediates exquisitely 
strong gene activation by this class of drug candidates.
A role for ltr12 activation in the anti-cancer 
effects of HDAC inhibitors
The mechanisms by that HDAC is exert their 
observed anti-cancer effects are not yet fully understood. 
HDACs remove acetyl groups from histone tails, and 
hypoacetylated chromatin is overall associated with 
transcriptional silencing [33, 34]. Histone deacetylation is 
commonly observed in human cancer and might stimulate 
the repression of important tumorsuppressive genes, 
thereby supporting tumorigenesis and possibly invasion 
and metastasis [39, 52, 53]. Accordingly, the inhibition of 
HDACs reverses these effects, and tumor proliferation is 
suppressed. LTR12-driven genes appear to be particularly 
susceptible to regulation by HDACs, not only in testicular 
cancer cells but in a wide variety of human cancers. This 
makes it plausible that the activation of LTR12-driven 
genes is indeed responsible for anti-tumor effects of 
HDAC inhibitors. At least the gene TNFRSF10B turned 
out as a mediator of apoptosis by HDAC inhibitors in our 
previous studies [19].
Impact of nF-Y on ltr12 promoter activity
The identification of genomic sites of transcription 
factors entailed the finding that many of them bind 
to specific families of repetitive sequences [54]. The 
rationale for assaying NF-Y here was based on the finding 
that the trimer binds to selected HERV-LTRs, in particular 
LTR12 sequences [27, 54]. HDAC inhibitors increase 
the association of NF-Y with LTR12 (Figure 5), whereas 
the depletion of NF-Y attenuates both baseline and TSA-
induced expression of LTR12-driven genes (Figure 6). 
In general, NF-Y inactivation is detrimental both for the 
basal and for the induced expression of LTR12-driven 
genes.The exception, the proapototic TNFRSF10B, shows 
an opposite behavior upon NF-YA vs NF-YB inactivation 
and joins a discrete set of pro-apoptotic mRNA genes 
which are differentially regulated upon inactivation of the 
two subunits [49]. What is the specific role of NF-Y in 
the activation of LTR12 promoters by HDAC inhibitors? 
Essentially, two non mutually exclusive mechanisms can 
be envisioned. Firstly, the effect might be entirely indirect, 
through hyperacetylation of neighboring nucleosomes 
and facilitated promoter access for transcription factors 
and cofactors, with the help of NF-Y. In the second 
scenario, HDAC inhibitors might impact directly on 
NF-Y, as suggested by binding of both histone acetyl 
transferases and HDACs to it [32, 35]. NF-YB/NF-YC 
show resemblance to H2B/H2A, respectively, and harbor 
important conserved lysine residues [25]. Since some of 
these are acetylated in core histones, notably in H2B, it is 
possible that they are targets of acetylation in NF-YB as 
well. Some of them are in contact with the DNA phosphate 
backbone, in the nucleosome and in NF-Y/CCAAT. This 
model would suggest that NF-Y is more stably bound to 
CCAAT boxes by removal of acetylation of such lysines 
through HDACs. However, NF-Y binding to LTR12 
promoters is, if anything, increased in vivo after HDAC 
inhibition (Figure 5), while transcriptional activation is 
nonetheless NF-Y-dependent (Figure 6). Of note, previous 
in vitro studies did not detect increased binding of NF-Y 
to the TBP-2 CCAAT in vitro when analyzing NF-Y from 
SAHA-treated cells [55]. Thus, we suggest an alternative 
model according to that NF-Y acetylationsrepresent 
signals for the recruitment of cofactors, as it was shown 
for the RFP repressor on the TBP-2 promoter [56]. 
Impact of HdAc inhibitors on cells from multiple 
tumor species
Interestingly, treatment with HDAC inhibitors did 
not only induce LTR12-regulated gene expression in 
testicular cancer cells, as reported previously [19, 20], but 
also in a set of human cancer cells derived from different 
tissues. SAHA (vorinostat) was approved by the US Food 
and Drug Administration for the treatment of cutaneous 
T-cell lymphoma in 2006 [45], as was romidepsin (FK228) 
in 2009 [57]. Both Mocetinostat (MGCD 0103) and 
Entinostat (MS-275) are currently undergoing clinical 
trials for the treatment of various cancer types, including 
lymphomas and solid tumors [44, 58, 59]. Our findings 
raise the possibility that LTR12 activation may contribute 
to these drug efficacies in a broader variety of cancers than 
hitherto anticipated. Moreover, the induction of LTR12-
driven transcription may also serve as a biomarker for 
the efficacy of the drugs in individual tumors. Thus, 
HDAC inhibitors may prove useful in a broad variety of 
tumors. Of note, this anticipated drug efficacy may not 
reveal itself when tested on endogenous animal tumors. 
Only humans and apes show the described insertion of 
LTR12s upstream of proapoptotic genes [19, 20]. Thus, 
genetically engineered mouse (GEM) tumor models will 
not show a comparable gene expression pattern in their 
cancers upon HDAC inhibitor treatment. In contrast, when 
using xenograft models, derived from patients or cell 
lines, HDAC inhibitors may reveal their full potential for 
treating a broad spectrum of human cancers.
Oncotarget33494www.impactjournals.com/oncotarget
MAterIAls And MetHods
cell culture
GH (testicular cancer), H1299 (adenocarcinoma 
of the lung), HeLa (cervical carcinoma) and U2OS 
(osteosarcoma) cells were maintained in Dulbecco’s 
Modified Eagle medium supplemented with 10% FBS. 
Ovcar-3 (ovarian carcinoma), K562 (chronic myelogenous 
leukemia) and HuT-78 (cutaneous T-cell lymphoma) cells 
were maintained in RPMI 1640 medium with 10% FBS. 
The HDAC inhibitors Trichostatin A (Sigma-Aldrich), 
SAHA, Mocetinostat, Entinostat, PCI-34051, Droxinostat 
and Tubastatin A hydrochloride (all Selleckchem) were 
dissolved in DMSO and added as indicated. Corresponding 
amounts of DMSO alone were added to controls.
Quantitative mrnA analysis by qrt-Pcr
Total RNA was isolated using TRIzol® (Invitrogen), 
followed by reverse transcription with Moloney Murine 
Leukemia Virus reverse transcriptase (New England 
Biolabs) and a mixture of oligo(dT) and random nonamer 
primers. A SYBR Green master mix including Taq 
polymerase (Primetech) was used for real-time PCR. The 
primer sequences are shown in Supplemental Table S4. 
PCR conditions were as follows: initial denaturation 2 min 
at 95°C, followed by 40 cycles of 95°C for 15 sec and 
60°C for 60 sec. Gene expression levels were normalized 
to RPLP0or to RSP20 as reference genes as indicated and 
calculated using the 2- ∆∆Ct method.
chromatin immunoprecipitation (chIP)
ChIP experiments were conducted as described [60]. 
For the immunoprecipitation of specific target proteins, 
chromatin from approximately 2 x 106 cells was incubated 
with 2 µg anti-NF-YB antibody (PAb001, Genespin, 
Italy) or corresponding amounts of anti-IgG antibody 
(ab46540, Abcam) and 30 µl protein A/G plus agarose 
beads (Santa Cruz). After multiple washing steps and 
purification, the ChIP samples were analyzed by qPCR. 
The primer sequences were designed according to the 
target sequences(Supplemental Table S3) and are shown in 
Supplemental Table S4. The precipitated amounts of DNA 
are presented as the percentage of input. As an internal 
negative control to exclude unspecific antibody binding, 
the inactive promoter region of myoglobin gene MB was 
analyzed. Cyclin B1 gene CCNB1 served as a positive 
control [49]. PCR conditions were as follows: initial 
denaturation 10 min at 95°C, followed by 40 cycles of 
95°C for 15 sec and 60°C for 60 sec, and final elongation 
5 min at 72°C.
In-silico prediction
Sequence information of 22 LTR12 promoter 
elements (SupplementalTable S1) was retrieved from the 
UCSC Genome Browser (hg19) and analyzed regarding 
the presence of putative NF-Y binding sites by ALGGEN 
PROMO (8.3 version of TRANSFAC) [61, 62]. The 
species was defined as human only, and the dissimilarity 
margin was set to be equal or less than 5%. Next, LTR12 
sequences were aligned using CLUSTALW2 with 
GAP penalties set to 25 (open), 0.20 (extension) and 5 
(distances). In Supplemental Figure S2, the insilico-
predicted NF-Y binding sites were highlighted in green to 
visualize their position.
chIP-seq data analysis
Based on the NF-YA and NF-YB binding 
information provided by Fleming et al. [27] and bed-
files containing all LTR12, LTR2 or LTR7B locations in 
the human genome, VENN diagrams were created using 
the Galaxy/Cistrome platform [63]. The information was 
retrieved from GEO (http://www.ncbi.nlm.nih.gov/geo/), 
and the following data sets were used. GSM935429, 
GSM935433, GSM935408, GSM935508, GSM935506 
and GSM935507.
lentiviral transduction
Scrambled control (shSC), NF-YA (shNF-YA) and 
NF-YB (shNF-YB) shRNAs were cloned into the pLKO.1 
vector (Sigma Aldrich). Viral supernatants expressing 
sh-scramble (control vector), sh-NF-YA and sh-NF-YB 
were prepared by transfecting HEK293T packaging cells. 
Briefly, shRNA plasmids and second generation packaging 
plasmids (VSVG and pCMV-dR8.74) were transfected 
into HEK293T cells. Lentivirus-containing supernatants 
were collected 48 h after transfection, filtered and frozen 
until use.
Hela cells were transduced with sh-SC or sh-NF-
YA or sh-NF-YB, treated with DMSO or TSA (final 
concentration 2μM) 54 hours after transduction, and 
collected at 18 hrs after treatment. Knockdown and 
treatment efficiency were assayed by PCR on cDNAs and 
by Western blot analysis on whole cell protein extracts 
using anti-NF-YA (Santa Cruz), anti NF-YB (GeneSpin), 
anti H3K9Ac (Abcam) and anti-Vinculin (Sigma) 
antibodies. Total RNA was prepared by Trizol extraction 
and reverse transcribed using the Iscript cDNA Synthesis 
kit (BIORAD 170-8890).
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Immunoblot analysis
After SDS-polyacrylamide gel electrophoresis and 
transfer on nitrocellulose, blots were incubated overnight 
with antibodies to PARP (Santa Cruz, sc-8007) or Caspase 
3 (Cell Signaling Technologies 9662), each diluted 1:1000 
in TBST with 4% BSA, followed by incubation with 
secondary antibodies coupled to peroxidase (1:10000) and 
chemiluminescent detection.
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